Clinical Trials
Open
Phase
Accrual
54%
SWOG Clinical Trial Number
S2104
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10-14-2021
Closed
Phase
Accrual
83%
SWOG Clinical Trial Number
S2001
Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects
Status Notes
Activation, Effective 12/04/2020, 3:00 pm eastern
Research Committee(s)
Gastrointestinal Cancer
Activated
12-04-2020
Closed
10-23-2025
ClinicalTrials.gov Registry Number
NCT04548752
Open
Phase
Accrual
83%
SWOG Clinical Trial Number
S1922
Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Status Notes
The study referenced above is open for participation effective Monday, December 16, 2019 at 2:00 p.m. Eastern.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-16-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1815
A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
Status Notes
This study permanently closed to accrual effective 2/15/21.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-03-2018
Closed
02-15-2021
Closed
Phase
Accrual
42%
SWOG Clinical Trial Number
S1613
A Randomized Phase II Study of Pertuzumab and Trastuzumab (TP) compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification
Status Notes
Step 1 is permanently closed to accrual effective December 31, 2021.
Step 2 is permanently closed to accrual effective March 31, 2022.
Step 2 is permanently closed to accrual effective March 31, 2022.
Research Committee(s)
Gastrointestinal Cancer
Activated
10-09-2017
Closed
12-31-2021
Closed
Phase
Accrual
86%
SWOG Clinical Trial Number
S1513
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC- 737664) in Metastatic Pancreatic Cancer
Status Notes
Effective Immediately (12/13/2017) S1513 is permanently closed. Patients currently receiving ABT-888 (Veliparib) must discontinue the experimental treatment but may continue on FOLFIRI alone. Patients on both arms should continue study follow-up.
Research Committee(s)
Gastrointestinal Cancer
Activated
09-01-2016